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ABSTRACT 
THE EFFECTS OF TRANEXAMIC ACID ON MORTALITY RATE IN 
 TRAUMA PATIENTS COMPARED TO TRAUMA PATIENTS  
WITH NO TRANEXAMIC ACID TREATMENT 
by Bradley Earl Tolar 
December 2016 
Traumatic injury is the leading cause of death for many age groups. 
Traumatic accidents caused over 130,000 deaths in the United States in 2014. 
This DNP project studied the effects of Tranexamic acid on mortality rate in 
trauma patients.  After the completion of a needs assessment at a local level II 
trauma center, a literature review was performed.  The literature showed a 
decrease in mortality rate when patients were administered Tranexamic acid 
within 3 hours of injury with statistically significant statistics.  Also, the data from 
the literature showed no correlation between vascular occlusive events and 
Tranexamic acid use in trauma patients. Second, a practice change proposal 
was drafted including the statistics found in the literature review.  This proposal 
was presented to available trauma surgeons at a local level II trauma center in 
south Mississippi.  Last, the trauma surgeons were asked to fill out a brief survey 
asking if they would be willing to change their practice based off the information 
provided.  The surgeons were not willing to change their practice, but their 
practice was currently up to date with the recommendations included in the 
practice change proposal.  Due to the project spanning over 2 years in time, the 
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previously performed needs assessment was outdated by the completion of the 
project.   
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CHAPTER I – INTRODUCTION 
Clinical Problem Statement 
Traumatic injuries are unplanned, life altering events that can affect a 
family with no warning.  Traumatic events are leading causes of mortality in many 
different age groups, especially young people (CDC, 2014).  While comorbidities 
such as heart disease, respiratory disease, stroke, and cancer are responsible 
for the deaths of many older individuals, trauma accidents still claim the lives of 
many older individuals too (CDC, 2014).  In a 2014 survey, the Centers for 
Disease Control found that traumatic accidents (or unintentional injuries) were 
the leading cause of death for people age 1 through age 44 in the United States 
(CDC, 2014).  The goals of this DNP project were to find evidence of Tranexamic 
acid administration reducing mortality rate in trauma patients, and to present a 
practice change proposal to local trauma surgeons.   
Needs Assessment 
Upon choosing the trauma patient population to study for the DNP project, 
a needs assessment was completed at a local level II trauma center.  At that time 
in April 2014, the use of Tranexamic acid in the trauma patient population was 
inconsistent at best.  One of the trauma surgeons was an advocate for its use, 
two of the trauma surgeons did not ever use the drug, and the other three 
surgeons used it on occasion.  With all available literature and statistics showing 
better patient outcomes, the project was started as a practice change proposal. 
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PICOT question 
How does the administration of Tranexamic acid affect mortality rate in 
trauma patients compared to trauma patients receiving no Tranexamic acid or 
placebo?  The patient population is acute trauma patients over the age of 16 
being admitted to a nearby hospital for surgical intervention to minimize blood 
loss.  The intervention is administration of Tranexamic acid in the preoperative, 
intraoperative, and postoperative phases of care.  The control group will be the 
group of patients who do not receive Tranexamic acid or who receive placebo 
treatment (depending on the trial in which they were in).  The outcome measured 
will be mortality rate of patients for treatment versus control groups.  The 
timeframe the variable will be measured in will differ between the trials, but they 
will all be within the first 30 days after surgery. 
Significance of the Project 
The main goal of this DNP project was to expand the use of Tranexamic 
acid among trauma surgeons at a local level II trauma center.  This was achieved 
by submitting a practice change proposal to the trauma surgeons with the results 
of the literature review included.  The trauma patient population was studied in 
the available literature in an effort to see if Tranexamic acid decreases mortality 
rate as compared to a control group not receiving Tranexamic acid or receiving a 
placebo treatment. 
Traumatic accidents are leading causes of death in many age groups 
(CDC, 2014).  The reason for death from trauma is due to severe hemorrhage 
limiting the oxygen carrying capacity of the blood and oxygen delivery to the 
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tissues.  Tranexamic acid is an antifibrinolytic drug that works by impeding 
fibrinolysis.  Fibrinolysis is the body’s own way of breaking down blood clots to 
make sure that the blood clots do not become problematic, such as those 
causing stroke, pulmonary embolus, deep vein thrombus, or myocardial 
infarction.  By impeding fibrinolysis, the body would not break down clots, but 
would further strengthen the clots that form.  This may lead to less hemorrhage 
and more stable trauma patients by maintaining adequate hemoglobin and 
hematocrit concentrations in the body. 
Theoretical Framework 
The nursing theory chosen to guide the research is Roy’s adaptation 
model. “According to this model, problems in adaptation materialize when the 
adaptive systems of a person are unable to respond to stimuli from internal or 
external environments” (Butts & Rich, 2015, p. 410).  This statement mimics the 
problems affecting the trauma patient in that the patient is unable to respond to 
other stimuli to survive.  The major elements involved in Roy’s adaptation model 
are adaptation, person, environment, health, and goal of nursing (Roy, 2009).  
The drug chosen, Tranexamic acid, will ultimately help with adaptation of the 
patient to the stressful traumatic injury.  The environment would include the 
traumatic accident that the patient suffered as well as the stress of the surgery 
that the patient is enduring.  Also, the environment of the hospital and the 
postoperative care unit that the patient is assigned to will affect the patient.  The 
health of the patient would be compromised, but Tranexamic acid has been 
shown to improve the health in terms of mortality rate.  The last major element of 
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Roy’s adaptation model is goal of nursing.  The goal of nursing through this 
project will be to improve trauma patient outcomes by expanding the use of 
Tranexamic acid among local trauma surgeons at a local level II trauma center. 
The fit between the DNP project and Roy’s adaptation model are near 
perfect.  Roy’s adaptation model states that there is never a perfect homeostatic 
state but that body systems adapt to try and meet a given need depending of the 
situation (Roy, 2009).  In the project’s population, the body’s homeostasis is lost 
by a traumatic injury which causes great risk for significant hemorrhage.  The 
cardiovascular stability is at risk and the body tries to adapt by causing a 
tachycardia to combat the hypotension associated with the hemorrhage.  
Tranexamic acid will look to help the homeostatic mechanisms that sometimes 
fail with excessive blood loss.   
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CHAPTER II – REVIEW OF LITERATURE 
Tranexamic acid is a drug that is relatively new to the trauma patient 
population.  Tranexamic acid is currently used with great success in patient 
populations at risk for excessive bleeding including: cardiac surgical patients, 
obstetric/gynecologic patients with heavy menstrual cycles, and orthopedic 
surgical patients.  Some side effects that have been potentially linked to 
Tranexamic acid include: stroke, deep vein thrombosis and pulmonary embolus.  
Tranexamic acid has been used in trauma patients and during trauma surgeries, 
but many physicians have not incorporated this drug into their practice, as 
discovered from a needs assessment performed at a local level II trauma center.  
Also, there are no published clinical guidelines available for Tranexamic acid in 
the trauma patient population.  The purpose of this literature review will be to 
provide a risk-benefit analysis of Tranexamic acid in relation to the treatment of 
trauma surgical patients.  The topic of discussion will be centered around the 
effect Tranexamic acid has on mortality rate in the trauma patient population as 
compared to trauma patients that do not receive this treatment.  Other important 
points that will be reviewed include the dosing of Tranexamic acid, the timing of 
Tranexamic acid administration in relation to injury, and incidence of blood 
transfusion in patients receiving treatment as compared to patients not receiving 
Tranexamic acid treatment. 
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Anatomy and Physiology of the Trauma Patient 
Nagelhout and Plaus (2014) defined traumatic injury as “a result of an 
external force that ultimately disrupts normal structure and function of the body.  
In most situations, the initial cause of injury is not a result of genetics or 
environmental exposure, but circumstance and misfortune” (Nagelhout & Plaus, 
2014, p. 914).  Nagelhout and Plaus (2014) further state that traumatic injury is 
the leading cause of death for people under 40 years of age.  Hoffman added to 
this point by stating that trauma can cause excessive bleeding by disruption of 
blood vessels and that more than one-third of trauma patients will die of 
exsanguination (Hoffman, 2004).  This capstone project seeks to improve patient 
outcomes in trauma patients. 
Trauma patients often present to the hospital with multiple injuries, some 
of which are not apparent upon initial physical assessment (Gruen et al., 2012).  
Patients can have spleen or liver lacerations that are not diagnosed until the 
patient has had adequate imaging scans to confirm internal bleeding.  The 
patient can sustain closed head injuries with subdural or epidural hematomas, 
which lead to altered mental status and increased intracranial pressure.  Also, 
numerous types of orthopedic injuries are possible in trauma patients (Barash, 
Cullen, Stoelting, Cahalan, & Stock, 2009).  All of these injuries can possibly lead 
the patient to excessive blood loss.  This can cause a state of hypovolemia 
leading to hypotension rather quickly (Gruen et al., 2012).  Hypovolemia must be 
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treated aggressively to restore the circulating volume in order to perfuse all vital 
organs (Butterworth, Mackey, & Wasnick, 2013). 
Often times, the trauma patient will require blood transfusion to maintain 
an adequate hemoglobin and hematocrit (Gruen et al., 2012).  Hemoglobin is 
responsible for carrying oxygen from the lungs while the blood transports this 
oxygen to the tissues for extraction.  If the concentration of hemoglobin falls too 
low, the tissues will not receive adequate oxygenation, even if the volume status 
is adequate.  It is necessary to keep an even balance of not only the volume 
status, but also enough hemoglobin in the circulating blood to transport oxygen to 
the tissues (Guyton & Hall, 2006). 
Clotting Cascade and Hemostasis 
To understand how Tranexamic acid works, one must first have a basic 
understanding of the clotting cascade and hemostasis.  Hemostasis simply 
defined is reduction or prevention of blood loss.  This is initially caused by local 
vasoconstriction at the site of vascular trauma.  The vasoconstriction is caused 
by the platelet’s release of thromboxane A2, which is a potent vasoconstrictor.  
Upon vascular injury, this vasoconstriction occurs to limit the amount of blood 
loss while a platelet plug is formed to close the site of blood loss (Guyton & Hall, 
2006). 
The clotting cascade is a very complicated process consisting of more 
than 50 substances.  Clotting takes place in three essential steps.  First, a 
complex cascade of chemical reactions involving 12 or more coagulation factors 
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occurs in response to a vascular injury, and leaves an end product known as a 
prothrombin activator.  Second, this product helps in the conversion of 
prothrombin to thrombin.  Last, this helps turn fibrinogen into fibrin, which 
ultimately forms a clot.  The initial clot starts a positive feedback loop that 
promotes more clotting (Guyton & Hall, 2006). 
After the clot has slowed or stopped bleeding, fibrinolysis begins to occur.  
Fibrinolysis breaks down the clot so it does not become pathologic and cause a 
deep vein thrombus or pulmonary embolus.  The plasma contains plasminogen 
that is converted to plasmin when activated.  Plasmin’s main job is to digest fibrin 
fibers and some other procoagulants.  Therefore, when plasmin is formed, it will 
cause the clot to be broken down so it does not become pathologic (Guyton & 
Hall, 2006). 
As previously discussed, there are over 50 substances that contribute to 
the clotting of blood.  Some of these substances are procoagulants, leading the 
body to cause clots.  Some of these substances are called anticoagulants, 
leading the blood to be thinner and less prone to clot (Guyton & Hall, 2006). 
Hypercoagulable states 
A hypercoagulable state is one in which there is an abundance of 
procoagulant factors.  A hypercoagulable state is considered positive when there 
has been some type of vascular injury, such as with a trauma patient.  This 
hypercoagulable state is partially responsible for forming the fibrin clot that 
eventually leads to cessation of blood loss.  Hypercoagulable states other than 
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with vascular injury are usually unwanted and can lead to pathologic clots such 
as deep vein thrombus, pulmonary embolus, stroke, or myocardial infarction 
(Guyton & Hall, 2006).  These 4 disease states can be caused by blood clots that 
block the normal flow of blood and eventually cause hypoxia to the tissues distal 
to the site of the clot. 
Hypocoagulable state 
A hypocoagulable state is one in which there is an abundance of 
anticoagulant factors (Guyton & Hall, 2006).  In the presence of vascular injury, 
this could lead to excessive blood loss.  However, there are many medical 
conditions that necessitate patients to remain in a pharmacologically induced 
hypocoagulable state (Guyton & Hall, 2006).  Some of these include: history of 
cardiac dysrhythmias, stroke, deep vein thrombus, pulmonary embolus, and 
coronary artery disease.  Most of these disease processes are caused from a 
previous hypercoagulable state which caused the patient to suffer some type of 
injury (Guyton & Hall, 2006).  In turn, they are prescribed medications that work 
to inhibit different specific parts of the clotting cascade to induce a 
hypocoagulable state.  This will help reduce the unwanted effects of pulmonary 
embolus, deep vein thrombus, stroke, and heart attack. 
Drugs that Affect Coagulation 
To cause a hypocoagulable state, a drug must inhibit a certain step in the 
clotting cascade. There are many classifications of these drugs based on what 
step in the clotting cascade they effect.  One category of drugs, called 
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anticoagulants, work to thin the blood by inhibiting a particular step of the clotting 
cascade.  Anticoagulants include: heparin, low-molecular-weight heparin, 
Coumadin, and direct thrombin inhibitors such as Argatroban and Pradaxa 
(dabigatran).  There are also antiplatelet drugs that work to cause a 
hypocoagulable state.  These drugs work directly on the circulating platelets to 
cause them not to agglutinate as easily.  Antiplatelet drugs include: nonsteroidal 
anti-inflammatory drugs, Plavix (clopidigrel), and Ticlid (ticlodipine HCl).  There 
are also herbal drugs which are usually not taken for the specific effect of 
hypocoagulation, but that also have that effect.  This category of drugs is 
important to be aware of as patients often do not know that their herbal 
medications have side effects affecting coagulation.  Herbal medications causing 
hypocoagulation of the blood include garlic, ginger, ginkgo, and fish oil.  The 
herbal medication known as black cohosh can cause the blood to be 
hypercoagulable.  The main procoagulant medication is Vitamin K.  This drug can 
be used as the reversal agent for a patient with increased bleeding times due to 
Coumadin.  Vitamin K is necessary for the production of many clotting factors in 
the body.  Antifibrinolytics is another class of drugs that cause hypercoagulation.  
These drugs do not make the blood clot quicker, but they do improve the strength 
of the clot.  Antifibrinolytics include Tranexamic acid and Aminocaproic acid 
(Nagelhout & Plaus, 2014). 
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Tranexamic Acid 
Tranexamic acid was the drug reviewed for this DNP project. Tranexamic 
acid is an antifibrinolytic drug.  As previously discussed, fibrinolysis is the internal 
process of breaking down the clot once it has slowed or stopped bleeding.  
Fibrinolysis is part of a system of checks and balances making sure hemostasis 
is well regulated.  After a clot has formed, blood flow is increased to the area and 
thromboxane A2 and adenosine diphosphate (two potent vasoconstrictors) are 
washed away to allow for increased flow of blood.  This increase in blood flow 
allows the body’s own tissue plasminogen activator (tPA) and urokinase to arrive 
at the area with the intact clot.  The body’s tPA and urokinase are catalysts in 
converting plasminogen (already located in the clot) into plasmin.  The plasmin is 
then able to degrade the fibrin into fibrin degradation products and the clot is then 
digested (Nagelhout & Plaus, 2014).  Tranexamic acid works to prevent 
fibrinolysis from occurring.  Its chief mechanism of action is to block the 
conversion of plasminogen to plasmin.  With no active plasmin, the fibrin clot is 
not broken down (Hensley, Martin, & Gravlee, 2013).  The goal in trauma 
patients is to stop the blood loss from occurring so that perfusion can be 
maintained to the vital organs.  By stopping the premature breakdown of fibrin 
clots, trauma patients will have more adequate clotting to reduce blood loss and 
maintain function of vital organs (Gruen et al., 2012). 
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Studies 
When searching the available literature for Tranexamic acid’s use in 
trauma patients, two studies were a recurring reference in almost all articles.  
The first of these studies, Clinical Randomisation of an Antifibrinolytic in 
Significant Hemorrhage-2 (CRASH-2) trial, was conducted in 2010.  The second 
study, the Military Application of Tranexamic Acid in Trauma Emergency 
Resusciation (MATTERS) trial, was conducted in 2012.  Most articles found on 
the selected population cited one or both of these two studies and looked at them 
in different ways.  While the MATTERS trial looked specifically at military 
administration of Tranexamic acid and CRASH-2 trial looked at civilian 
administration of the drug, both trials have data that is applicable to this project. 
CRASH-2 trial 
The CRASH-2 trial was conducted in 2010, and although it is greater than 
5 years old, it is considered a gold standard in this patient population. Nearly all 
articles cite this trial and/or MATTERS trial in their reviews.  CRASH-2 trial 
investigators studied the effects of Tranexamic acid on a total of 20,211 patients 
across 40 countries and 274 hospitals.  CRASH-2 trial includes civilian patients 
suffering from traumatic injuries presenting with significant hemorrhages, as 
evidenced by tachycardia and hypotension (Guerriero et al., 2011). 
In the CRASH-2 trial, 10,060 patients were given Tranexamic acid as a 
treatment following their traumatic accident, while 10,151 patients were given 
placebos.  Of the 20,211 total patients in this study, 1,063 patients died from 
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hemorrhage.  Of these 1,063 mortalities, 489 were from the Tranexamic acid 
treatment group, while 574 were from the control group that received placebos.  
When comparing mortality of treatment group versus control group, 4.9 percent 
of the treatment group died from hemorrhage and 5.7 percent of the control 
group died from hemorrhage. Relative risk statistics show a 15% decrease in risk 
of mortality due to hemorrhage when receiving Tranexamic acid when compared 
to patients in control group (RR 0.85, CI 0.76 to 0.96; P = 0.0077) (Perel, Ker, 
Morales Uribe, & Roberts, 2013).  “These figures suggest that administration of 
Tranexamic acid can reduce the risk of death from bleeding” (Livingstone, 2013, 
p. 25).  “The pooled data showed that antifibrinolytic drugs reduce the risk of 
death from any cause by 10% (RR 0.90, 95% CI 0.85 to 0.97; P = 0.003).  This 
estimate is based primarily on data from the CRASH-2 trial of Tranexamic acid, 
which contributed 99% of the data” (Ker, Roberts, Shakur, & Coats, 2015, p. 2). 
Timing of Administration.  According to Livingstone (2013), patients in the 
CRASH-2 trial were placed into 1 of 3 groups in relation to timing of initial dose of 
Tranexamic acid: within 1 hour of injury, between 1 and 3 hours of injury, longer 
than 3 hours after injury.  The data concluded that patients had a greater chance 
of survival when administration of Tranexamic acid was within 1 hour after injury, 
or between 1 and 3 hours after injury.  When timing of administration was longer 
than 3 hours from time of injury, mortality rate increased (RR 1.44, 95% CI 1.12 
to 1.84; P = 0.004) (Livingstone, 2013). 
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Researchers compared Tranexamic acid’s use in trauma patients to tissue 
Plasminogen Activator (t-PA) use in ischemic stroke patients (Meurer, 2013).  
When Tranexamic acid is given within 3 hours of injury the data shows promising 
results of decreased mortality, but after 3 hours the results show more harm than 
good.  Meurer (2013) states that t-PA was shown to reduce the number of 
patients with disabilities from stroke by 14 percent when given within 3 hours of 
onset of symptoms.  Nearly 20 years after this finding was confirmed with 
research and a large trial, it is still not fully used in treatment facilities.  Meurer 
calls for Tranexamic acid to “become standard of care for trauma patients 
worldwide long before the 20th anniversary of the CRASH-2 trial” (Meurer, 2013, 
para. 8). 
Guerriero, Cairns, Perel, Shakur, and Roberts (2011) found that early 
treatment with Tranexamic acid is necessary to improve outcomes.  They also 
found that when Tranexamic acid is administered within 3 hours of injury, the risk 
of death is reduced by 13 percent (RR 0.87, 95% CI 0.81 to 0.95).  Guerriero et 
al. (2011) claim that it can be harmful to administer Tranexamic acid outside of a 
three hour window from the time of injury (Guerriero et al., 2011). 
Dosing of Administration.  Dosing of Tranexamic acid has been a question 
across other patient populations.  There was no variance in the dose of 
Tranexamic acid in the CRASH-2 or MATTERS trials.  Too large of a dose can 
cause a hypercoagulable state that could lead to pulmonary emobolus, stroke, or 
deep vein thrombus.  Too small of a dose would not produce the therapeutic 
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effect of slowing down fibrinolysis.  The only dose mentioned in regards to 
trauma patients was referenced from the MATTERS trial.  Livingstone (2013) 
said the dose of Tranexamic acid in trauma patients was a 1 gram bolus given 
over 10 minutes followed immediately by 1 gram given slowly over the next 8 
hours (Livingstone, 2013).  The initial bolus is given to load all of the receptors so 
that fibrinolysis is slowed or stopped.  The second dose is given slowly over 8 
hours to keep a steady state of the active drug in circulation.  With a half life of 3 
hours, the active drug could be metabolized out of circulation before the need for 
the drug is complete (Nagelhout & Plaus, 2014). 
Adverse Outcomes of Tranexamic Acid?  There are concerns surrounding 
Tranexamic acid administration causing adverse vascular occlusive events, 
especially in at risk patients.  Patients with specific risks to these events are 
those patients with a history of such events including: deep vein thrombus, 
pulmonary embolus, myocardial infarction, and stroke.  According to one 
reviewer of the CRASH-2 trial “there is no evidence that antifibrinolytics have an 
effect on the risk of vascular occlusive events (quality of evidence: Moderate)” 
(Ker et al., 2015, p. 2). 
There has also been much discussion as to whether Tranexamic acid has 
any effect on the number of patients needing blood transfusion after traumatic 
injury.  Being that blood transfusion carries many risks, this is another topic of 
interest among the possible benefits of Tranexamic acid administration.  
According to the CRASH-2 trial “there is no evidence that antifibrinolytics have an 
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effect on the receipt of blood transfusion (quality of evidence: High)” (Ker et al., 
2015, p. 2). 
Cost Effectiveness.  According to Livingstone’s review of the CRASH-2 
trial, Tranexamic acid is a much cheaper alternative to the numerous blood 
products given to patients with traumatic hemorrhage.  In the United Kingdom, 
the four vials of Tranexamic acid needed to treat a patient was roughly 20 times 
cheaper than one unit of packed red blood cells (Livingstone, 2013).  Meurer 
(2013) called Tranexamic acid “inexpensive” at less than 100 dollars and said it 
was cheaper than the cost of starting an IV line and administering a liter of saline.  
Guerriero et al. (2011) conducted a review with the single objective of studying 
cost effectiveness.  While their explanation of cost was much more in depth, it 
still is considered a cost effective strategy.  “Tranexamic acid is not only life 
saving… but also that it is a highly cost effective intervention if administered 
routinely to bleeding trauma patients in high, middle, and low income countries” 
(Guerriero et al., 2011, p. 5). 
MATTERS trial 
The MATTERS trial is considered a gold standard of studies among 
trauma patients receiving Tranexamic acid.  The MATTERS trial was conducted 
in 2012 and is a retrospective study that examined medical records of military 
trauma patients over a 24-month period.  In total, there were 896 patients with 
combat-related injuries.  The study included all patients who suffered from 
combat injuries and had to receive at least one unit of packed red blood cells 
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within 24 hours of admission to the treatment facility.  Many of these patients 
received greater than 10 units of blood products and were categorized as 
receiving a massive transfusion. 
Two hundred ninety three of the 896 total patients received Tranexamic 
acid while 603 did not receive Tranexamic acid.  Roughly 50 percent of patients 
receiving Tranexamic acid died within 30 days of receiving treatment.  Sixty four 
percent of patients not receiving Tranexamic acid died in the same time frame 
(Livingstone, 2013).   
Three hundred twenty one of the 896 total patients received mass 
transfusion.  One hundred twenty five of these 321 patients received Tranexamic 
acid while 196 did not receive Tranexamic acid. Forty three percent of patients 
receiving a mass transfusion and Tranexamic acid died within 30 days of 
admission to hospital; compared with 64 percent of patients receiving a mass 
transfusion and no Tranexamic acid treatment (Livingstone, 2013). 
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CHAPTER III – METHODS 
For this DNP project, a needs assessment was completed at a local level 
II trauma center at the start of the project in early 2014. Following the needs 
assessment, a review of the literature regarding the effects of Tranexamic acid 
on mortality rate in trauma patients was conducted.  A comprehensive literature 
search was conducted to find relevant articles related to trauma patients 
receiving Tranexamic acid as a treatment for preventing hemorrhage.  Multiple 
electronic databases were used during this search, but the majority of articles 
were found in CINAHL, MEDLINE, and PubMed.  The terms Tranexamic acid, 
trauma, txa, antifibrinolytic, and hemorrhage were all used singly and in 
combination.  Many articles were duplicated in searches across other databases.  
All articles found on this topic cited one of two trials that have taken place in this 
population: the MATTERS trial or the CRASH-2 trial.  Inclusion criteria for all 
databases included articles written in the English language, full text articles only, 
publication dates between 2010 and present time, patients were victims of a 
traumatic injury, ages of patients were determined by the individual trials in which 
they were in.  Exclusion criteria included studies not published in the English 
language, studies that did not include full text, studies conducted prior to 2010, 
and patients in any other category besides trauma. 
Data was gathered from other studies, namely the MATTERS trial and the 
CRASH-2 trial, that have been previously completed.  The most important data 
collected was the effect of Tranexamic acid on mortality.  There was also 
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research performed on dose of administration and timing of administration in 
relation to injury. 
Following the literature review, a practice change proposal to trauma 
surgeons at a local level II trauma center was developed.  The practice change 
proposal was compiled using evidence from the literature on how to successfully 
use Tranexamic acid in the trauma patient population to maximize the drug’s 
potential and decrease the mortality rate of trauma patients.  This proposal also 
stated whether or not the use of Tranexamic acid is found to increase or 
decrease the amount of blood products needed postoperatively.
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CHAPTER IV – DISCUSSION 
After completing the review of literature and successfully completing 
Institutional Review Board (IRB) at The University of Southern Mississippi (USM), 
a practice change proposal was drafted and presented to available trauma 
surgeons at a level II trauma center in south Mississippi.  After presentation of 
the proposal, a brief survey was administered to assess surgeons’ willingness to 
change practice.  
There was a total of 5 trauma surgeons currently practicing at the trauma 
center.  An individual attempt was made to schedule a meeting time with all 5 of 
the surgeons for presentation of the findings and practice change proposal.  Two 
of the 4 surgeons were unavailable or uninterested.  A response was never 
obtained from 1 surgeon.  Ultimately, two surgeons were presented the findings 
and practice change proposal. 
After obtaining consent from both participants, the findings of the literature 
review were covered along with statistical evidence.  The findings included 
statistics of Tranexamic acid’s effect on mortality rate, incidence of vascular 
occlusive events, incidence of blood transfusion, and cost effectiveness.  Next, a 
brief survey was administered that asked if the participant would consider a 
practice change based on the information presented.  Both participants answered 
no to this question.  Since initial meeting with these surgeons over two years 
ago, much effort has been made to improve their use of the drug through 
research of their own.  This group of surgeons has access to literature that was 
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not available through USM libraries database.  Their use of Tranexamic acid in 
trauma patients in on par with the recommendations made based off the 
literature review. 
Further Research 
This project could be expanded upon in the future in the form of a 
retrospective chart review on trauma patients that have received Tranexamic 
acid to examine its effects on mortality rate in the local hospital.  Also, further 
research with more equipped databases could assess the effect of Tranexamic 
acid on patients with a history of vascular occlusive events. One topic that was 
never debated in the literature was the dose of Tranexamic acid.  It was a set 
dose of 1000 mg IV bolus followed by 1000 mg IV slowly over the next 8 hours.  
All other variables were debated but this was not and the dose of administration 
could be studied for further research. 
DNP Essentials 
The DNP essentials covered in this DNP project include numbers III, IV, 
VI.  Essential III is clinical scholarship and analytical methods for evidence-based 
practice (American Association of Colleges of Nursing [AACN], 2006).  This 
essential was met through completion of the literature review and analyzing the 
associated statistics.  Essential IV is information systems/technology and patient 
care technology for the improvement and transformation of health care (AACN, 
2006).  This essential was met using the literature databases to search for 
literature related to the project.  Essential VI is interprofessional collaboration for 
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improving patient and population health outcomes (AACN, 2006).  This essential 
was met through collaboration with trauma surgeons to provide the highest level 
of quality care for trauma patients.   
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CHAPTER V – SUMMARY 
The purpose of this capstone project was to evaluate the effects of 
Tranexamic acid on mortality rate in the trauma patient population and to draft a 
practice change proposal for local trauma surgeons.  The primary outcome 
studied was mortality rate of trauma patients receiving Tranexamic acid, while 
also studying the effects on vascular occlusive events and incidence of blood 
transfusions.  A review of the literature was performed and the results of 
previously performed trials were analyzed.  Next, a practice change proposal was 
drafted and presented to available surgeons at a level II trauma center in south 
Mississippi.  A survey was presented to the surgeons after presentation of the 
practice change proposal.  Due to their recent overhaul of their Tranexamic acid 
protocol for trauma patients, none of the surgeons surveyed were willing to 
consider a practice change. 
The review of literature found that mortality rate was decreased in trauma 
patients receiving Tranexamic acid and that it was statistically significant.  The 
literature also showed no difference in vascular occlusive events for trauma 
patients receiving Tranexamic acid versus trauma patients with no Tranexamic 
acid treatment. 
The literature showed a decrease in mortality rate when trauma patients 
are treated with Tranexamic acid.  That was one of the goals of this study.  While 
the practice change proposal did not encourage trauma surgeons to change their 
practice, the trauma patients in this area are receiving treatment with Tranexamic 
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acid that is up to date with current literature.  The data and literature available to 
the trauma surgeons was superior to the literature available to the author.  Due to 
the availability of the literature, the trauma patients in this area have a better 
chance of survival due to the use of Tranexamic acid in the local level II trauma 
center. 
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APPENDIX A – Long Consent Form 
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APPENDIX B – Clinical Evaluation Piece 
 
Brad Tolar 
Clinical Evaluation Piece for Capstone Project 
 
1. Would you consider a practice change based on this information 
presented today? YES or NO 
 
2. If the answer is yes, what practice change would you implement? 
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APPENDIX C – Practice Change Proposal 
 
CAPSTONE PROJECT FINDINGS & PRACTICE CHANGE PROPOSAL 
 Trauma is the leading cause of death for ages 1-44 (CDC, 2014) 
o 3rd leading cause of death for ages 45-64 (CDC, 2014) 
 Tranexamic acid is an antifibrinolytic  
o Impedes fibrinolysis: blocks conversion of plasminogen to plasmin 
(plasmin normally breaks down clots) 
o Does not lead to more clots forming, only strengthens pre-existing 
clots 
 CRASH-2 trial (Clinical Randomisation of an Antifibrinolytic in Significant 
Hemorrhage-2 trial), 2010 
o 20,211 civilian patients 
 10,060 were given Tranexamic acid as treatment 
 10,151 were given placebos as treatment 
o 1,063 deaths from hemorrhage 
 489 of these deaths were administered Tranexamic acid; this 
is 4.9% of the treatment group;  
 547 of these deaths were administered placebo; this is 5.7% 
of the control group 
 Relative risk stats show a 15% decrease in risk of mortality 
due to hemorrhage when receiving Tranexamic acid (RR 
0.85, 95% CI 0.76 to 0.96) (Perel, Ker, Morales, & Roberts, 
2013) 
o Mortality rate from hemorrhage decreased by 15% (0.85, 95% CI 
0.76 to 0.96; P = 0.0077) when compared to patients in control 
group (Ker, Roberts, Shakur, & Coats, 2015) 
o Treatment with Tranexamic acid within 1 hour of injury was 
associated with a 32% decrease (RR 0.68, 95% CI 0.57 to 0.82; P 
< 0.0001) in risk of death due to hemorrhage (Ker, Roberts, Shakur, 
& Coats, 2015) 
o Treatment with Tranexamic acid between 1 and 3 hours after injury 
was associated with a 21% reduction (RR 0.79, 95% CI 0.64 to 
0.97; P = 0.03) in risk of death due to hemorrhage  (Ker, Roberts, 
Shakur, & Coats, 2015) 
o Mortality rate from hemorrhage increased when timing of 
administration was greater than 3 hours after injury (Livingstone, 
2013). Guerriero et al. (2011) also says timing of administration 
must be within 3 hours of injury and data shows 44% increase in 
risk of death due to hemorrhage when administration of Tranexamic 
acid is more than 3 hours after injury (RR 1.44, 95% CI 1.12 to 
1.84; P = 0.004) (Ker, Roberts, Shakur, & Coats, 2015) 
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o Livingstone (2013) said CRASH-2 used a dose of 1 gram bolus 
over 10 minutes, followed by 1 gram slowly infused over the next 8 
hours 
 MATTERS trial (Military Application of Tranexamic acid in Trauma 
Emergency Resuscitation trial), 2012 
o 896 military patients 
o 293 received Tranexamic acid treatment 
 Roughly 50% died within 30 days of injury/treatment 
(Livingstone, 2013) 
o 603 did not receive Tranexamic acid treatment 
 64% died within 30 days of injury and no treatment 
(Livingstone, 2013) 
o 321 received mass transfusion (greater than 10 units) 
 125 received Tranexamic acid  
 43% died within 30 days 
 196 did not receive Tranexamic acid 
 64% died within 30 days 
 Pooled data from both trials suggests that Tranexamic acid decreased risk 
of death from any cause by 10% (RR 0.90, 95% CI 0.85 to 0.97; P = 
0.003) (Ker, Roberts, Shakur, & Coats, 2015) 
 Adverse Outcomes?? 
o “There is no evidence that antifibrinolytics have an effect on the risk 
of vascular occlusive events (quality of evidence: Moderate)” (Ker, 
Roberts, Shakur, & Coats, p. 2, 2015) 
 Vascular occlusion (RR 0.69, 95% CI 0.44 to 1.07; P = 
0.096) 
 Stroke (RR 1.60, 95% CI 0.52 to 4.89; P= 0.40 
 Pulmonary Embolism (RR 0.86, 95% CI 0.46 to 1.61; P = 
0.63) 
o “There is no evidence that antifibrinolytics have an effect on the 
receipt of blood transfusion (RR 0.98, 95% CI 0.96 to 1.01; P = 
0.21) (quality of evidence: High)” (Ker, Roberts, Shakur, & Coats, p. 
2, 2015) 
 Cost Effectiveness 
o Livingstone (2013) said in the United Kingdom, the Tranexamic 
acid treatment was 20 times cheaper than one unit of PRBCs 
o Cost of Tranexamic acid for FGH is $24.47 per 1 gram dose 
 
PROPOSAL 
 More widespread use of Tranexamic acid in trauma patients (age 16 and 
over) with risk of significant bleeding 
o This does not apply to patients with traumatic brain injury with no 
other injuries 
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 1st dose must be given within 3 hours of injury. Times longer than 3 hours 
are associated with increased risk of death 
 Dose used in literature was 1 gram IV loading dose over 10 minutes 
followed by 1 gram IV given slowly over the next 8 hours 
o Dose was not researched in the literature, but this seemed to be 
standardized among trials 
 
Further Research? 
 Dosing of administration, as this seems to not be debated anywhere for 
trauma patients 
 Outcomes on patients with history of vascular occlusive events 
 Statistical analysis among trauma patients at FGH (cost-prohibitive for me) 
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APPENDIX D – Signed Support Leter 
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APPENDIX E  - IRB Approval Letter 
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